Edition:
United States

Bio Rad Laboratories Inc (BIO)

BIO on New York Consolidated

218.26USD
28 Apr 2017
Change (% chg)

$0.48 (+0.22%)
Prev Close
$217.78
Open
$218.07
Day's High
$218.94
Day's Low
$216.52
Volume
291,165
Avg. Vol
200,714
52-wk High
$219.34
52-wk Low
$135.94

Latest Key Developments (Source: Significant Developments)

Bio Rad Laboratories Inc says expects to achieve long-term currency-neutral revenue growth of approximately 3% to 5%
Monday, 13 Mar 2017 08:31am EDT 

Bio Rad Laboratories Inc : Bio Rad Laboratories Inc says expects to achieve long-term currency-neutral revenue growth of approximately 3% to 5% . Bio Rad Laboratories Inc says expects to achieve currency-neutral EBITDA margin of greater than 20% by 2020 . Bio Rad Laboratories Inc says reiterated its 2017 financial outlook .FY2017 earnings per share view $2.80, revenue view $2.11 billion -- Thomson Reuters I/B/E/S.  Full Article

Bio Rad Laboratories reports Q2 profit $0.61 per share
Wednesday, 3 Aug 2016 04:15pm EDT 

Bio Rad Laboratories Inc : Second-Quarter reported revenues were $516.8 million, an increase of 2.1 percent . Bio-Rad reports second-quarter 2016 financial results .Net income for Q2 of 2016 was $18.0 million, or $0.61 per share.  Full Article

Bio-Rad Laboratories Inc's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Monday, 21 Dec 2015 04:21pm EST 

Bio-Rad Laboratories:Received U.S. Food and Drug Administration clearance to market its TANGO infinity system in the U.S.The system automates routine blood typing and screening testing procedures for patients and donors.  Full Article

Bio-Rad Laboratories Inc announces U.S. FDA pre-market approval for BioPlex 2200 HIV Ag-Ab Assay
Tuesday, 28 Jul 2015 04:15pm EDT 

Bio-Rad Laboratories Inc:Received U.S. Food and Drug Administration pre-market approval to offer its BioPlex 2200 HIV Ag-Ab assay, the company's 5th generation HIV diagnostic test.  Full Article

More From Around the Web

Fitch Affirms Bio-Rad's IDR at 'BBB-'; Outlook Stable

(The following statement was released by the rating agency) AUSTIN, April 05 (Fitch) Fitch Ratings has affirmed the ratings of Bio-Rad Laboratories, Inc. (Bio-Rad), including the 'BBB-' Issuer Default Rating (IDR). The ratings apply to approximately $437 million of debt at Dec. 31, 2016. The Rating Outlook is Stable. A full list of rating actions follows at the end of this release. KEY RATING DRIVERS Evolving Capital Allocation Strategy: Bio-Rad recently announced long-term targets for revenue g